Publisher： Karger
E-ISSN： 1662-6575|8|2|285-289
ISSN： 1662-6575
Source： Case Reports in Oncology, Vol.8, Iss.2, 2015-07, pp. : 285-289
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Duodenal adenocarcinoma is a rare malignancy and carries a poor prognosis. The role of adjuvant therapy and the optimal chemotherapy regimen remain largely unclear. Treatment with trastuzumab results in prolonged survival in gastroesophageal cancer if human epidermal growth factor receptor 2 (HER2) is overexpressed or amplified in tumor cells. However, unlike gastric adenocarcinomas, duodenal cancers seem to rarely harbor HER2 amplification or overexpression. We report the case of a patient with HER2-positive stage III duodenal adenocarcinoma who has received adjuvant chemotherapy including trastuzumab.
Related content
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (ELECTRONIC), Vol. 44, Iss. 2, 2018-02 ,pp. :
Access to resources
Recommend
Primary Duodenal Adenocarcinoma without Stenosis: A Case Report with a Brief Literature Review
Case Reports in Oncology, Vol. 7, Iss. 2, 2014-07 ,pp. :
DISEASES OF THE ESOPHAGUS (ELECTRONIC), Vol. 28, Iss. 4, 2015-05 ,pp. :